Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR Advances June 16, 2026
- Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System June 16, 2026
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026

AZD0516: Phase 1 Trial for This STEAP2 ADC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by MaxTJ101 Enters Testing for Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxSpanish Study Confirms Real-World Success of Apalutamide in Prostate Cancer
/in Retrospective studies/by MaxFrom Proteins to Pathways: PDGrapher’s Shift in Drug Discovery
/in Artificial Intelligence/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxMemantine Shows Promise Against Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial
/in Clinical Trial, Metastatic, Phase 3/by Max